Study guide

10.1 Obstructive Ventilatory Defects: Asthma, COPD, Emphysema, Chronic Bronchitis, Bronchiectasis

Certified Pulmonary Function Technologist CPFT

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Overview & NBRC Certification Requirements

1.1 NBRC PFT Exam Logistics, Format, and Scoring Criteria 1.2 Scope of Practice, Candidate Admission Pathways, and Credential Maintenance 1.3 Professional Standards, Ethics, and Patient Safety in Diagnostic Testing

2 Chapter 2: Spirometry Equipment & Sensors

2.1 Volume-Displacement Spirometers: Water-Seal, Rolling-Seal, Bellows 2.2 Flow-Sensing Pneumotachometers: Fleisch, Lilly, Vortex, Turbine, Pitot Tube, Ultrasonic 2.3 Calibration Standards & 3-Liter Syringe Quality Control Verification

3 Chapter 3: Body Plethysmography & Hardware

3.1 Body Plethysmograph Principles: Pressure, Volume, and Variable-Pressure-Constant-Volume Design 3.2 Plethysmograph Calibration, Pressure Transducers, and Shutter Mechanics 3.3 Quality Control, Isothermal Corrections, and Leak Detection in Plethysmography

4 Chapter 4: Gas Analyzers, Environmental Sensors, & Infection Control

4.1 Rapid and Multi-Gas Analyzers: Infrared, Zirconium, Mass Spec, Electrochemical, Thermal Conductivity 4.2 Environmental Sensors, Barometric Pressure, Temperature, and BTPS Correction Factors 4.3 Infection Control, Equipment Decontamination, Disposable Filters, and Spaulding Classification 4.4 Monitors: Pulse Oximeters, Blood Pressure Devices, and ECG Equipment 4.5 Gas Delivery Systems, Valves, Absorbers, and Aerosol / Inhaler Devices

5 Chapter 5: Spirometry Protocols & ATS/ERS Criteria

5.1 Forced Vital Capacity (FVC) and Slow Vital Capacity (SVC) Testing Protocols 5.2 ATS/ERS Spirometry Acceptability, Repeatability, and Usability Criteria 5.3 Peak Expiratory Flow Rate (PEFR), Maximum Voluntary Ventilation (MVV), and Flow-Volume Loops

6 Chapter 6: Lung Volume Determination Protocols

6.1 Open-Circuit Nitrogen Washout Method: Principles, Equipment, and Calculation 6.2 Closed-Circuit Helium Dilution Method: Principles, Equipment, and Calculation 6.3 Thoracic Gas Volume (TGV/FRCpleth) and Comparison of Lung Volume Methods

7 Chapter 7: Diffusing Capacity & Bronchial Challenge Testing

7.1 Single-Breath Carbon Monoxide Diffusing Capacity (DLCO) Testing Protocol 7.2 DLCO Calculations, Hemoglobin/COHb/Altitude Corrections, and VA 7.3 Bronchial Provocation Testing: Methacholine Challenge, Exercise-Induced Bronchospasm, and EIB Protocols 7.4 Inhaled Medication Delivery Technique and Patient Education

8 Chapter 8: Cardiopulmonary Exercise & ABG Testing

8.1 Cardiopulmonary Exercise Testing (CPET) Protocols, VO2max, and Anaerobic Threshold 8.2 Six-Minute Walk Test (6MWT) Protocol, Desaturation Monitoring, and O2 Titration 8.3 Arterial Blood Gas (ABG) Sampling, Allen Test, Analyzer Maintenance, and Quality Control 8.4 Pulse Oximetry and Oxygen Assessment: Principles, Limitations, and Titration Data 8.5 CO-Oximetry / Hemoximetry: Measurement, Dyshemoglobins, and Clinical Implications 8.6 Exercise Monitoring Data: Blood Pressure Response and ECG Rhythm Analysis

9 Chapter 9: Reference Values & PFT Calculations

9.1 Predicted Value Equations, Reference Populations, and GLI 2012 / ATS/ERS 2022 Standards 9.2 BTPS, STPD, and ATPS Conversion Formulas and Calculations 9.3 Gas Exchange Formulas, Alveolar Air Equation, and Mechanical Calculations

10 Chapter 10: Pattern Recognition & Clinical PFT Interpretation

10.1 Obstructive Ventilatory Defects: Asthma, COPD, Emphysema, Chronic Bronchitis, Bronchiectasis 10.2 Restrictive Ventilatory Defects: Parenchymal, Chest Wall, and Neuromuscular Disorders 10.3 Mixed Ventilatory Defects, Isolated Diffusion Defects, and Reversibility Protocols

11 Chapter 11: Artifact Recognition & Quality Assurance

11.1 Spirometry Artifacts: Hesitation, Coughing, Early Termination, Glottic Closure, Leak 11.2 Lung Volume and DLCO Artifacts: Panting Frequency, Shutter Leaks, Breath-Hold Failure 11.3 Quality Control Charts, Westgard Rules, and Laboratory Quality Assurance

12 Chapter 12: Documentation, Compliance, & Emergency Safety

12.1 PFT Reporting Standards, Tabular Formats, and Interpretation Graphics 12.2 CPT Billing Codes, ICD-10 Coding, HIPAA Privacy, and EHR Compliance 12.3 Emergency Preparedness, Contraindications, and Patient Safety Management in PFT Lab

13 Chapter 13: Specialized Procedures, Home Testing & Longitudinal Data

13.1 Respiratory Muscle Strength: MIP, MEP, SNIP, and Cough Peak Flow 13.2 Sputum Sample Collection: Spontaneous and Induced Specimens 13.3 Home Testing Instruction: Home Spirometry, Peak Flow Diaries, and Home Oximetry 13.4 Pediatric Pulmonary Function Testing and Upright Versus Supine Spirometry 13.5 Serial Pulmonary Function Testing, Clinical History, Demographics, and Laboratory Quality Management

10.1 Obstructive Ventilatory Defects: Asthma, COPD, Emphysema, Chronic Bronchitis, Bronchiectasis

Key Takeaways Explain This Topic AI

Airflow obstruction is physiologically defined by an FEV1/FVC ratio below the Lower Limit of Normal (LLN) or post-bronchodilator FEV1/FVC < 0.70 according to GOLD guidelines.

GOLD grades post-bronchodilator FEV1 percent predicted as GOLD 1 at 80% or above, GOLD 2 at 50-79%, GOLD 3 at 30-49%, and GOLD 4 below 30%; the ATS/ERS 2005 impairment bands and the ATS/ERS 2022 z-score bands use different cut points and must not be mixed with GOLD.

Expiratory flow-volume loop morphology in obstructive defects demonstrates classic concavity (scooping) during forced expiration due to dynamic small airway collapse.

Distinguishing emphysema from chronic bronchitis relies on DLCO: emphysema exhibits reduced DLCO from loss of alveolar-capillary surface area, whereas chronic bronchitis demonstrates normal DLCO with preserved alveolar membrane structure.

Air trapping is defined by an elevated Residual Volume (RV > 120% predicted or RV/TLC > 35-40%), while pulmonary hyperinflation is confirmed by an elevated Total Lung Capacity (TLC > 120% predicted).

Last updated: August 2026

10.1 Obstructive Ventilatory Defects: Asthma, COPD, Emphysema, Chronic Bronchitis, Bronchiectasis

Pattern recognition in pulmonary function test (PFT) interpretation requires a systematic, step-by-step approach. The primary objective when evaluating spirometry is to determine whether airflow is hindered during forced exhalation. Obstructive ventilatory defects are defined by pathologically reduced expiratory flow rates relative to lung volume, originating from airway narrowing, structural collapse, inflammation, or loss of parenchymal elastic recoil.

This section outlines the diagnostic algorithm for obstructive ventilatory defects, severity classification standards, flow-volume loop characteristics, the differentiation of air trapping versus hyperinflation, and clinical characteristics of asthma, emphysema, chronic bronchitis, and bronchiectasis essential for the NBRC CPFT examination.

Diagnostic Algorithm for Obstructive Ventilatory Defects

The fundamental physiological hallmark of an obstructive defect is a disproportionate reduction in the rate at which gas can be forcefully exhaled from the lungs relative to the total volume exhaled. Interpretation begins with evaluating forced spirometry parameters.

Step 1: Evaluating the F E V 1 / F V C FEV_1/FVC FE V 1 ​ / F V C Ratio

To establish the presence of an obstructive ventilatory defect, the technologist or interpreting physician must first examine the ratio of Forced Expiratory Volume in 1 second ( F E V 1 FEV_1 FE V 1 ​ ) to Forced Vital Capacity ( F V C FVC F V C ):

Primary Standard (ATS/ERS Guidelines): An obstructive defect is present when the measured F E V 1 / F V C FEV_1/FVC FE V 1 ​ / F V C ratio falls below the Lower Limit of Normal (LLN) , corresponding to a Z-score < − 1.645 < -1.645 < − 1.645 (below the 5th percentile of a healthy non-smoking reference population).

GOLD Criteria (COPD Management): The Global Initiative for Chronic Obstructive Lung Disease (GOLD) utilizes a fixed post-bronchodilator threshold of F E V 1 / F V C < 0.70 FEV_1/FVC < 0.70 FE V 1 ​ / F V C < 0.70 ( 70 % 70\% 70% ) to define persistent airflow limitation in adults suspected of having COPD.

Clinical Pearl: Using the age-adjusted LLN prevents the overdiagnosis of obstruction in elderly patients (who naturally lose elastic recoil with age) and prevents underdiagnosis in young adults (who normally have baseline F E V 1 / F V C FEV_1/FVC FE V 1 ​ / F V C ratios > 80 % > 80\% > 80% ).

Step 2: Severity Grading — Three Systems That Must Not Be Confused

Once an obstructive defect is established, severity is graded from F E V 1 FEV_1 FE V 1 ​ . Three published schemes exist, and mixing their cut points is one of the most common interpretation errors:

Scheme Basis Bands

GOLD grades (COPD) Post-bronchodilator F E V 1 FEV_1 FE V 1 ​ % predicted GOLD 1 ≥ 80 % \ge 80\% ≥ 80% ; GOLD 2 50 50 50 – 79 % 79\% 79% ; GOLD 3 30 30 30 – 49 % 49\% 49% ; GOLD 4 < 30 % < 30\% < 30%

ATS/ERS 2005 impairment F E V 1 FEV_1 FE V 1 ​ % predicted Mild > 70 % > 70\% > 70% ; Moderate 60 60 60 – 69 % 69\% 69% ; Moderately severe 50 50 50 – 59 % 59\% 59% ; Severe 35 35 35 – 49 % 49\% 49% ; Very severe < 35 % < 35\% < 35%

ATS/ERS 2022 interpretive F E V 1 FEV_1 FE V 1 ​ z-score Mild − 1.65 -1.65 − 1.65 to − 2.50 -2.50 − 2.50 ; Moderate − 2.51 -2.51 − 2.51 to − 4.00 -4.00 − 4.00 ; Severe < − 4.00 < -4.00 < − 4.00

The table below is the GOLD grading scheme, which is what most NBRC-style COPD items use: GOLD Grade Label F E V 1 (% Predicted, post-BD) Clinical Interpretation GOLD 1 Mild ≥ 80 % Minimal exertional symptoms; early airway changes GOLD 2 Moderate 50 % to 79 % Exertional dyspnea; noticeable exercise limitation GOLD 3 Severe 30 % to 49 % Frequent exacerbations; dyspnea with daily activities GOLD 4 Very Severe < 30 % Severe chronic dyspnea; resting hypoxemia or cor pulmonale \begin{array}{cccc}

  • \hline
  • \text{GOLD Grade} & \text{Label} & FEV_1 \text{ (\% Predicted, post-BD)} & \text{Clinical Interpretation} \\
  • \hline
  • \text{GOLD 1} & \text{Mild} & \ge 80\% & \text{Minimal exertional symptoms; early airway changes} \\

\text{GOLD 2} & \text{Moderate} & 50\%\text{ to }79\% & \text{Exertional dyspnea; noticeable exercise limitation} \\

\text{GOLD 3} & \text{Severe} & 30\%\text{ to }49\% & \text{Frequent exacerbations; dyspnea with daily activities} \\

\text{GOLD 4} & \text{Very Severe} & < 30\% & \text{Severe chronic dyspnea; resting hypoxemia or cor pulmonale} \\

\hline

\end{array} GOLD Grade GOLD 1 GOLD 2 GOLD 3 GOLD 4 ​ Label Mild Moderate Severe Very Severe ​ FE V 1 ​ (% Predicted, post-BD) ≥ 80% 50% to 79% 30% to 49% < 30% ​ Clinical Interpretation Minimal exertional symptoms; early airway changes Exertional dyspnea; noticeable exercise limitation Frequent exacerbations; dyspnea with daily activities Severe chronic dyspnea; resting hypoxemia or cor pulmonale ​ ​

Expiratory Flow-Volume Loop Morphology

Visual analysis of the graphic flow-volume curve provides immediate diagnostic clues regarding airflow limitation. In healthy individuals, the expiratory curve rises rapidly to a sharp Peak Expiratory Flow Rate ( P E F R PEFR PEFR ) and declines linearly toward zero flow at maximum exhalation ( F V C FVC F V C ).

Characteristics of Obstructive Curves

Concavity / "Scooping": The hallmark of small airway obstruction is pronounced concavity (caving inward toward the volume axis) during the mid-to-late portion of the forced expiration curve. This represents reduced flow rates at lower lung volumes ( F E F 25 − 75 % FEF_{25-75\%} FE F 25 − 75% ​ , F E F 50 % FEF_{50\%} FE F 50% ​ , and F E F 75 % FEF_{75\%} FE F 75% ​ ).

Reduced Peak Expiratory Flow: In moderate to severe obstruction, P E F R PEFR PEFR is markedly depressed, and the peak shifts to the right (toward higher volume).

Prolonged Expiratory Time: Dynamic airway collapse and high airway resistance prolong the forced expiratory time ( F E T FET FET ), often requiring > 6 > 6 > 6 to 12 12 12 seconds for the patient to reach a complete plateau. Flow-Volume Loop Parameter Obstructive Pattern Manifestation Expiratory Curve Shape Concave / "Scooped" appearance during mid-to-late expiration Peak Expiratory Flow Rate (PEFR) Reduced; delayed achievement of peak flow Forced Expiratory Time (FET) Significantly prolonged (> 6-12 seconds) Expiratory Flow Rates ( F E F 25 − 75 % ) Severe reduction out of proportion to total volume \begin{array}{cc}

  • \hline
  • \text{Flow-Volume Loop Parameter} & \text{Obstructive Pattern Manifestation} \\
  • \hline
  • \text{Expiratory Curve Shape} & \text{Concave / "Scooped" appearance during mid-to-late expiration} \\
  • \text{Peak Expiratory Flow Rate (PEFR)} & \text{Reduced; delayed achievement of peak flow} \\
  • \text{Forced Expiratory Time (FET)} & \text{Significantly prolonged (> 6-12 seconds)} \\
  • \text{Expiratory Flow Rates } (FEF_{25-75\%}) & \text{Severe reduction out of proportion to total volume} \\
  • \hline

\end{array} Flow-Volume Loop Parameter Expiratory Curve Shape Peak Expiratory Flow Rate (PEFR) Forced Expiratory Time (FET) Expiratory Flow Rates ( FE F 25 − 75% ​ ) ​ Obstructive Pattern Manifestation Concave / "Scooped" appearance during mid-to-late expiration Reduced; delayed achievement of peak flow Significantly prolonged (> 6-12 seconds) Severe reduction out of proportion to total volume ​ ​

Air Trapping versus Pulmonary Hyperinflation

Airflow obstruction impairs gas emptying during exhalation, causing gas to become trapped behind narrowed or collapsed airways. Lung volume determinations via body plethysmography or gas dilution are required to distinguish air trapping from true hyperinflation .

1. Air Trapping

Air trapping occurs when gas remains trapped in the lungs at the end of a maximal exhalation due to premature closure of small conducting airways.

Diagnostic Criteria: Elevated Residual Volume ( R V > 120 % RV > 120\% R V > 120% predicted) or an elevated R V / T L C RV/TLC R V / T L C ratio ( > 35 % > 35\% > 35% to 40 % 40\% 40% ) .

Spirometric Effect: Because gas is trapped in the R V RV R V compartment, the usable Forced Vital Capacity ( F V C FVC F V C ) is reduced, even though Total Lung Capacity ( T L C TLC T L C ) remains within normal limits.

2. Pulmonary Hyperinflation

Pulmonary hyperinflation refers to an absolute enlargement of the total thoracic gas volume at maximal inspiration.

Diagnostic Criteria: Elevated Total Lung Capacity ( T L C > 120 % TLC > 120\% T L C > 120% predicted) .

Physiological Mechanism: Loss of pulmonary elastic recoil (as seen in emphysema) reduces the inward pull of the lungs, allowing the chest wall to expand outward and establish a larger equilibrium volume. Air Trapping = R V > 120 % predicted or R V T L C > 35 - 40 % ( T L C normal ) \text{Air Trapping} = RV > 120\% \text{ predicted or } \frac{RV}{TLC} > 35\text{-}40\% \quad (TLC \text{ normal}) Air Trapping = R V > 120% predicted or T L C R V ​ > 35 - 40% ( T L C normal ) Hyperinflation = T L C > 120 % predicted ( R V usually elevated as well ) \text{Hyperinflation} = TLC > 120\% \text{ predicted} \quad (RV \text{ usually elevated as well}) Hyperinflation = T L C > 120% predicted ( R V usually elevated as well )

Clinical Etiologies and Differential Diagnosis

Obstructive ventilatory defects encompass several distinct clinical entities. The NBRC CPFT examination tests the technologist's ability to differentiate these conditions using spirometry, lung volumes, diffusing capacity ( D L C O DLCO D L CO ), and bronchodilator responsiveness.

1. Asthma

Pathophysiology: Chronic inflammatory disorder of the airways characterized by bronchial hyperresponsiveness, smooth muscle bronchospasm, mucosal edema, and mucous plugging.

PFT Profile:

Spirometry reveals an obstructive defect ( F E V 1 / F V C < LLN FEV_1/FVC < \text{LLN} FE V 1 ​ / F V C < LLN ).

High Reversibility: Demonstrates significant improvement post-bronchodilator ( F E V 1 FEV_1 FE V 1 ​ or F V C FVC F V C increases by ≥ 12 % \ge 12\% ≥ 12% and ≥ 200 mL \ge 200\text{ mL} ≥ 200 mL ). Between acute exacerbations, spirometry may normalize completely.

D L C O DLCO D L CO Pattern: D L C O DLCO D L CO is normal or characteristically elevated ( > 100 % > 100\% > 100% to 120 % 120\% 120% predicted). Elevated D L C O DLCO D L CO in asthma occurs due to increased pulmonary capillary blood volume driven by heightened negative intrathoracic pressures during inspiratory efforts.

2. Chronic Obstructive Pulmonary Disease (COPD): Emphysema vs. Chronic Bronchitis

COPD represents a spectrum of progressive airflow limitation that is not fully reversible. It comprises two primary clinical phenotypes:

A. Emphysema

Pathophysiology: Permanent enlargement of airspaces distal to terminal bronchioles accompanied by destruction of alveolar walls and capillary beds, without obvious fibrosis. Primary etiologies include cigarette smoking and α 1 \alpha_1 α 1 ​ -antitrypsin deficiency.

PFT Profile:

Spirometry shows fixed obstruction ( F E V 1 / F V C < 0.70 FEV_1/FVC < 0.70 FE V 1 ​ / F V C < 0.70 ).

Lung volumes reveal marked hyperinflation ( T L C > 120 % TLC > 120\% T L C > 120% ) and severe air trapping ( R V > 150 % RV > 150\% R V > 150% ) .

D L C O DLCO D L CO Pattern: Markedly REDUCED ( < LLN < \text{LLN} < LLN ) . Alveolar septal destruction reduces the total surface area available for gas transfer and destroys the pulmonary capillary network.

B. Chronic Bronchitis

Pathophysiology: Chronic inflammation of the tracheobronchial tree defined clinically by a chronic productive cough for at least 3 consecutive months in 2 consecutive years. Characterized by mucous gland hyperplasia, goblet cell metaplasia, and bronchial wall thickening.

PFT Profile:

Spirometry shows obstruction ( F E V 1 / F V C < LLN FEV_1/FVC < \text{LLN} FE V 1 ​ / F V C < LLN ).

Lung volumes show moderate air trapping ( R V RV R V elevated, T L C TLC T L C normal or slightly elevated).

D L C O DLCO D L CO Pattern: NORMAL ( > LLN > \text{LLN} > LLN ) . Because alveolar capillary walls remain structurally intact, gas diffusing surface area is preserved.

3. Bronchiectasis

Pathophysiology: Irreversible structural dilation and destruction of major bronchi resulting from chronic, recurrent necrotizing infections (e.g., cystic fibrosis, primary ciliary dyskinesia).

PFT Profile:

Spirometry reveals moderate-to-severe airflow obstruction with disproportionately reduced mid-expiratory flow rates ( F E F 25 − 75 % FEF_{25-75\%} FE F 25 − 75% ​ ).

Copious sputum production can cause acute, transient fluctuations in flow rates.

D L C O DLCO D L CO ranges from normal to mildly decreased depending on underlying parenchymal involvement.

Diagnostic Matrix of Obstructive Disorders Clinical Condition F E V 1 / F V C T L C R V D L C O Bronchodilator Response Asthma < LLN Normal / High Elevated (attacks) Normal or ↑ Highly Reversible ( ≥ 12 % and 200 mL ) Emphysema < 0.70 ↑ ↑ ( > 120 % ) ↑ ↑ ↑ ( > 150 % ) ↓ ↓ ( < LLN ) Fixed / Minimal Reversibility Chronic Bronchitis < 0.70 Normal / Slightly ↑ ↑ ( 120 − 140 % ) Normal ( ≥ LLN ) Partial or Minimal Reversibility Bronchiectasis < LLN Normal / Slightly ↑ ↑ ( 120 − 140 % ) Normal / Mildly ↓ Variable \begin{array}{lccccc}

  • \hline
  • \text{Clinical Condition} & FEV_1/FVC & TLC & RV & DLCO & \text{Bronchodilator Response} \\
  • \hline

\text{Asthma} & < \text{LLN} & \text{Normal / High} & \text{Elevated (attacks)} & \text{Normal or } \uparrow & \text{Highly Reversible } (\ge 12\% \text{ and } 200\text{ mL}) \\

\text{Emphysema} & < 0.70 & \uparrow\uparrow (>120\%) & \uparrow\uparrow\uparrow (>150\%) & \mathbf{\downarrow\downarrow (< \text{LLN})} & \text{Fixed / Minimal Reversibility} \\

\text{Chronic Bronchitis} & < 0.70 & \text{Normal / Slightly } \uparrow & \uparrow (120-140\%) & \mathbf{\text{Normal } (\ge \text{LLN})} & \text{Partial or Minimal Reversibility} \\

\text{Bronchiectasis} & < \text{LLN} & \text{Normal / Slightly } \uparrow & \uparrow (120-140\%) & \text{Normal / Mildly } \downarrow & \text{Variable} \\

\hline

\end{array} Clinical Condition Asthma Emphysema Chronic Bronchitis Bronchiectasis ​ FE V 1 ​ / F V C < LLN < 0.70 < 0.70 < LLN ​ T L C Normal / High ↑↑ ( > 120% ) Normal / Slightly ↑ Normal / Slightly ↑ ​ R V Elevated (attacks) ↑↑↑ ( > 150% ) ↑ ( 120 − 140% ) ↑ ( 120 − 140% ) ​ D L CO Normal or ↑ ↓↓ ( < LLN ) Normal ( ≥ LLN ) Normal / Mildly ↓ ​ Bronchodilator Response Highly Reversible ( ≥ 12% and 200 mL ) Fixed / Minimal Reversibility Partial or Minimal Reversibility Variable ​ ​